ADXS News and Press, Advaxis From 05/26/22

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control ra...

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it will present data from the Phase 2 study of ADXS-503 in co...

ADXS-PSA in combination with KEYTRUDA ® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for pati...

Advaxis press release (OTC:ADXS): Q1 GAAP EPS of $0.00. As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents For further details see: Advaxis GAAP EPS of $0.00

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Priced Offering of $5 Million Convertible Redeemable Preferred Stock through a Private Placement MONMOUTH JUNCTION, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc...

Advaxis  press release (OTC:ADXS): FY GAAP EPS of -$0.14 beats by $0.03. Revenue of $3.24M (+1196.0% Y/Y) beats by $0.25M. As of October 31, 2021, Advaxis had cash and cash equivalents of $41.6 million. For further details see: Advaxis  GAAP EPS of -$0....

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc . (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 20...

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc . (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company entered into an agreement with certain institution...

Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients i...

OTC Markets Group Welcomes Advaxis, Inc. to OTCQX PR Newswire NEW YORK , Dec. 23, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, I...